Gamida Cell Ltd   (GMDA)
Other Ticker:  
Price: $0.3800 $0.04 12.393%
Day's High: $0.3837 Week Perf: -2.31 %
Day's Low: $ 0.34 30 Day Perf: -6.82 %
Volume (M): 2,762 52 Wk High: $ 2.51
Volume (M$): $ 1,050 52 Wk Avg: $1.08
Open: $0.35 52 Wk Low: $0.22

 Market Capitalization (Millions $) 47
 Shares Outstanding (Millions) 124
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) 24
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 4

Gamida Cell Ltd
Gamida Cell Ltd is a biotechnology company that specializes in the development of cell therapies for the treatment of various diseases, particularly cancer and rare genetic disorders. The company is known for its innovative approach to cell therapy, utilizing proprietary technologies to enhance the therapeutic potential of cells.

Gamida Cell's lead product candidate is called NiCord, which is being developed as a treatment for patients in need of a bone marrow transplant. NiCord is derived from umbilical cord blood and is designed to improve the availability and effectiveness of transplants for patients with hematologic malignancies and blood disorders.

The company also has a pipeline of other cell therapies in development, targeting different therapeutic areas such as solid tumors and genetic disorders. Gamida Cell's technologies aim to improve the engraftment and durability of cell therapies, offering potential advancements in the field of regenerative medicine.

Headquartered in Jerusalem, Israel, Gamida Cell collaborates with various partners, including pharmaceutical companies and research institutions, to advance its pipeline and broaden its reach in the global biotech industry.

   Company Address: 116 Huntington Avenue Boston 2116 MA
   Company Phone Number: 892-9080   Stock Exchange / Ticker: NASDAQ GMDA
   GMDA is expected to report next financial results on March 30, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Product Service News

Gamida Cell Presents Positive Data on Omidubicel's Efficacy in Hematopoietic Recovery and Infection Rates

Published Fri, Feb 23 2024 1:00 PM UTC

In recent data presented at the 2024 Tandem Meetings of ASTCT and CIBMTR, Gamida Cell showcased the results of their Expanded Access Program (EAP) for omidubicel. The presented data supported the positive outcomes observed in the Phase 3 trial, with regards to rates of hematopoietic recovery and infections following stem cell transplant with Omisirge (omidubicel-onlv). This ...

Gamida Cell Ltd

Gamida Cell Ltd's Q3 2023 Financial Report Shows Decline in Revenue to $0.673 Million, Raises Concerns Among Investors

Gamida Cell Ltd, a renowned biotechnology company, recently released its financial report for the fiscal third quarter of 2023. While the company's revenue and net earnings experienced a significant decline compared to the previous year, it showcased improving profit margins and promising growth opportunities through its proprietary nicotinamide (NAM) technology. Let's delve deeper into the numbers and examine the potential implications for the stock market.
Revenue and Net Earnings:
According to the report, Gamida Cell Ltd proclaimed $0.673 million in revenue for the fiscal third quarter of 2023. This figure represents a substantial decline from the $17.802 million reported in the corresponding period the previous year. This staggering decrease of -91.47% could raise concerns among investors and analysts about the company's performance.

Gamida Cell Ltd

Gamida Cell Ltd Reports Strong Operating Profit in Second Quarter of 2023

Gamida Cell Ltd, a biotechnology company in the pharmaceuticals sector, recently announced its operating profit for the fiscal period of April to June 2023. The company reported an operating profit of $18.802 million, which is an improvement from the $18.046 million reported in the same period last year. This positive news has instilled confidence in the market regarding Gamida Cell Ltd.
However, despite the increase in operating profit, Gamida Cell Ltd recorded a net shortfall of $0.000 million for the fiscal period ending June 30, 2023. This is a significant deviation from the bottom line of $18.554 million reported in the previous year. Despite this setback, the company's operating earnings grew by 4.19% to reach $18.802 million.


Gamida Cell Ltd's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com